HDL levels
This early company may be of interest for its drug that "raised HDL levels by approximately 20% and lowered blood triglycerides by approximately 40% in healthy subjects over a two-week period" in a phase I, they are supposed to report a phase I-II by the end of Q1.
"Liponex previously completed three Phase I human trials. These trials included one single-dose trial and two multi-dosage trials of two-week duration, both with and without placebo. These trials demonstrated that an unformulated version of CRD5 was safe and well tolerated with no significant adverse events. Efficacy data, although based on a small population in the Phase I trials, showed that CRD5 raised HDL levels by approximately 20% and lowered blood triglycerides by approximately 40% in healthy subjects over a two-week period.
On their phase I-II:
The "single-blinded Phase I/II dose-ranging trial was designed to enrol 50 dyslipidemic patients (patients with low HDL and high LDL). Following a dietary lead in period, patients were being given daily doses of the formulation of CRD5 in capsule form. Each patient was to receive a placebo dose plus three different doses of CRD5, with the total treatment time following dietary lead in totalling 12 weeks.
Greater than 50 patients have been enrolled in the clinical trial of which many of these patients have now completed the 1 gram, 3 gram and 5 gram dosing. Patient treatment remains ongoing. The primary endpoints for the trial are safety and an increase in serum HDL, with triglyceride and LDL reductions as secondary endpoints. The Company is expecting to report results from the trial by the end of the first quarter of 2007.
Liponex is a biopharmaceutical company specializing in developing products related to High Density Lipoprotein (HDL), often called "good cholesterol."
Market Data 
Markets 
AI
